Travere Therapeutics (NASDAQ:TVTX) Stock Price Crosses Below 200-Day Moving Average - What's Next?

Travere Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Shares slipped below the 200-day moving average, trading as low as $46.90 and last quoted at about $46.99, versus the average of $47.99.
  • Analyst sentiment remains positive overall: the consensus rating is “Moderate Buy” with a $72.55 price target, though recent firms adjusted targets in both directions.
  • Latest quarterly results were mixed: Travere reported a larger-than-expected loss of $0.55 per share, but revenue beat estimates at $224.56 million and grew 36.2% year over year. Insiders also sold about 1.29 million shares over the past 90 days.
  • Five stocks we like better than Travere Therapeutics.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $47.99 and traded as low as $46.90. Travere Therapeutics shares last traded at $46.9940, with a volume of 1,329,568 shares traded.

Wall Street Analysts Forecast Growth

TVTX has been the subject of several recent research reports. Zacks Research upgraded Travere Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Wednesday. Wedbush reiterated an "outperform" rating and issued a $76.00 price objective on shares of Travere Therapeutics in a research report on Tuesday, September 22nd. Guggenheim lowered their price objective on Travere Therapeutics from $89.00 to $78.00 and set a "buy" rating for the company in a research report on Wednesday, November 4th. Citigroup boosted their target price on Travere Therapeutics from $70.00 to $85.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Finally, TD Cowen lifted their target price on Travere Therapeutics from $60.00 to $75.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $72.55.

View Our Latest Analysis on TVTX

Travere Therapeutics Price Performance

The company has a quick ratio of 2.95, a current ratio of 3.00 and a debt-to-equity ratio of 26.72. The firm has a market capitalization of $4.51 billion, a price-to-earnings ratio of -36.43 and a beta of 1.11. The company has a fifty day moving average price of $54.23 and a two-hundred day moving average price of $47.99.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.49). The company had revenue of $224.56 million for the quarter, compared to analyst estimates of $195.29 million. Travere Therapeutics had a negative net margin of 18.66% and a negative return on equity of 185.69%. Travere Therapeutics's revenue was up 36.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.28 earnings per share. On average, equities research analysts expect that Travere Therapeutics, Inc. will post -0.90 EPS for the current fiscal year.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, CEO Eric Dube sold 243,735 shares of Travere Therapeutics stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $53.82, for a total transaction of $13,117,817.70. Following the completion of the transaction, the chief executive officer directly owned 432,886 shares of the company's stock, valued at $23,297,924.52. The trade was a 36.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Reed sold 37,500 shares of the company's stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $62.34, for a total transaction of $2,337,750.00. Following the sale, the insider directly owned 105,389 shares of the company's stock, valued at $6,569,950.26. This represents a 26.24% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,294,029 shares of company stock valued at $79,454,261 in the last ninety days. Insiders own 4.44% of the company's stock.

Hedge Funds Weigh In On Travere Therapeutics

Large investors have recently modified their holdings of the company. Jupiter Topco LLC purchased a new position in shares of Travere Therapeutics during the second quarter valued at approximately $643,299,000. Bank of America Corp DE bought a new stake in Travere Therapeutics during the 2nd quarter valued at approximately $259,527,000. Wellington Management Group LLP boosted its position in shares of Travere Therapeutics by 50.0% during the 2nd quarter. Wellington Management Group LLP now owns 1,533,080 shares of the company's stock valued at $87,094,000 after acquiring an additional 510,808 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Travere Therapeutics by 168.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,145,414 shares of the company's stock valued at $67,442,000 after purchasing an additional 718,109 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of Travere Therapeutics by 96.6% during the third quarter. Russell Investments Group Ltd. now owns 778,340 shares of the company's stock worth $45,829,000 after purchasing an additional 382,371 shares during the last quarter.

About Travere Therapeutics

(Get Free Report)

Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on kidney and metabolic disorders. The company was formerly known as Retrophin and adopted the Travere Therapeutics name in 2020. Its commercial products include FILSPARI (sparsentan), an oral treatment approved in the United States for adults with primary IgA nephropathy at risk of disease progression, and THIOLA EC (tiopronin), used to help prevent cystine kidney stones in people with cystinuria.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Travere Therapeutics Right Now?

Before you consider Travere Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.

While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines